thecardiologyadvisor.com3d
Sotatercept Trial Ends Due to Positive Clinical Program Efficacy Data
The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.
Healio4d
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
rarediseaseadvisor1d
Sotatercept-csrk’s Success in PAH Results in Early Termination of HYPERION Trial
The decision to terminate the HYPERION trial reflects a loss of clinical equipoise, making it unethical to continue the placebo-controlled study.
pharmaphorum4d
MSD leaps on FDA approval of PAH drug sotatercept
In addition to STELLAR, MSD is running the phase 3 HYPERION trial of sotatercept in newly diagnosed intermediate- and high-risk PAH patients, seeking to move it up the treatment pathway ...
appliedclinicaltrialsonline1d
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...
Managed Healthcare Executive2d
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH
Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...
Benzinga.com3d
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales of $200 million. Guidance: Merck expects fiscal year 2025 sales of $64.1 billion-$65.6 ...
pharmaphorum6d
Merck’s cardiovascular pipeline delivers at ACC
At the American College of Cardiology (ACC) meeting this week, Merck showcased two components of its cardiovascular pipeline – sotatercept for pulmonary arterial hypertension (PAH) and oral ...